This page shows the latest Moderna Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Flagship’s portfolio currently consists of over 40 companies, including Moderna, Denali Therapeutics, and Generate Biomedicines.
Moderna and Life Edit Therapeutics, an ElevateBio company, have entered into a strategic collaboration aimed at discovering and developing in vivo mRNA gene editing therapies for hard-to-treat diseases. ... Moderna’s partnership with Life Edit is not
I am confident that our technology and talent will be a highly strategic fit with Moderna.". ... OriCiro's synthetic biology and enzyme technologies will support Moderna's portfolio of therapeutics and vaccines, the company said.
Moderna, a biotech company specialising in messenger RNA (mRNA) therapeutics and vaccines, and the UK government have reached an agreement in principle for an mRNA Innovation and Technology Center in the ... UK. Throughout the COVID-19 pandemic, Moderna
After eight years of collaboration on mRNA-based therapeutics, AstraZeneca and Moderna have announced promising, early results for their candidate therapy AZD8601. ... Moderna’s pioneering mRNA therapeutics are designed to trigger the cellular
In 2013, AZ invested $240m in Moderna, signing an alliance at the time to discover mRNA therapeutics for cardiometabolic disease and selected oncology targets. ... Moderna Therapeutics’.
More from news
Approximately 2 fully matching, plus 17 partially matching documents found.
Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... Moderna Therapeutics has received $8m of the grant to fund early-stage trials of the vaccine and plans to submit an investigational new drug
Back to the immuno-oncology theme, near the end of June Merck &Co signed a collaboration agreement with Moderna Therapeutics to use Moderna's mRNA technology to develop personalised cancer vaccines. ... licence. 230. Moderna Therapeutics/ Merck &Co.
Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls
300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290. ... 144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options.
Commercialisation. Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast . ... Moderna Therapeutics / DARPA. R&D grant. mRNA therapeutics for biodefence targets (discovery).
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Oxford, UK-based Evox Therapeutics has appointed its new chief executive officer in the form of Tony de Fougerolles. ... Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.
Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.
US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair. ... Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's
Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.
Former Sanofi Pasteur policy head joins Moderna Therapeutics firm. Valera, one of Moderna Therapeutics' venture companies, has appointed Dr Michael Watson as its new president. ... Moderna's technology, coupled with its goal to deliver transformative
More from appointments
Approximately 3 fully matching, plus 5 partially matching documents found.
No results were found
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...